Primary Care Rx Market Offers Second-Rate Return On Investment, Bristol Says

The sales and marketing investment required to compete in the primary care market means that no drug company can perform well by remaining in the category, CFO Bonfield asserts. To maintain a presence in primary care, Bristol will increasingly turn to development partners, as it did to Merck for its dual PPAR agonist muraglitazar.